BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38321963)

  • 1. Selection-free precise gene repair using high-capacity adenovector delivery of advanced prime editing systems rescues dystrophin synthesis in DMD muscle cells.
    Wang Q; Capelletti S; Liu J; Janssen JM; Gonçalves MAFV
    Nucleic Acids Res; 2024 Mar; 52(5):2740-2757. PubMed ID: 38321963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-scale genome editing based on high-capacity adenovectors and CRISPR-Cas9 nucleases rescues full-length dystrophin synthesis in DMD muscle cells.
    Tasca F; Brescia M; Wang Q; Liu J; Janssen JM; Szuhai K; Gonçalves MAFV
    Nucleic Acids Res; 2022 Jul; 50(13):7761-7782. PubMed ID: 35776127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations.
    Maggio I; Stefanucci L; Janssen JM; Liu J; Chen X; Mouly V; Gonçalves MA
    Nucleic Acids Res; 2016 Feb; 44(3):1449-70. PubMed ID: 26762977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New advancements in CRISPR based gene therapy of Duchenne muscular dystrophy.
    Eslahi A; Alizadeh F; Avan A; Ferns GA; Moghbeli M; Reza Abbaszadegan M; Mojarrad M
    Gene; 2023 May; 867():147358. PubMed ID: 36914142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells.
    Ifuku M; Iwabuchi KA; Tanaka M; Lung MSY; Hotta A
    Methods Mol Biol; 2018; 1828():191-217. PubMed ID: 30171543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR Therapeutics for Duchenne Muscular Dystrophy.
    Erkut E; Yokota T
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing.
    Chemello F; Chai AC; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Atmanli A; Mireault AA; Liu N; Bassel-Duby R; Olson EN
    Sci Adv; 2021 Apr; 7(18):. PubMed ID: 33931459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy.
    Moretti A; Fonteyne L; Giesert F; Hoppmann P; Meier AB; Bozoglu T; Baehr A; Schneider CM; Sinnecker D; Klett K; Fröhlich T; Rahman FA; Haufe T; Sun S; Jurisch V; Kessler B; Hinkel R; Dirschinger R; Martens E; Jilek C; Graf A; Krebs S; Santamaria G; Kurome M; Zakhartchenko V; Campbell B; Voelse K; Wolf A; Ziegler T; Reichert S; Lee S; Flenkenthaler F; Dorn T; Jeremias I; Blum H; Dendorfer A; Schnieke A; Krause S; Walter MC; Klymiuk N; Laugwitz KL; Wolf E; Wurst W; Kupatt C
    Nat Med; 2020 Feb; 26(2):207-214. PubMed ID: 31988462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prime Editing Permits the Introduction of Specific Mutations in the Gene Responsible for Duchenne Muscular Dystrophy.
    Happi Mbakam C; Rousseau J; Tremblay G; Yameogo P; Tremblay JP
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.
    Pickar-Oliver A; Gough V; Bohning JD; Liu S; Robinson-Hamm JN; Daniels H; Majoros WH; Devlin G; Asokan A; Gersbach CA
    Mol Ther; 2021 Nov; 29(11):3243-3257. PubMed ID: 34509668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy.
    Domenig SA; Bundschuh N; Lenardič A; Ghosh A; Kim I; Qabrati X; D'Hulst G; Bar-Nur O
    Stem Cell Reports; 2022 Feb; 17(2):321-336. PubMed ID: 34995499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells.
    Maggio I; Liu J; Janssen JM; Chen X; Gonçalves MA
    Sci Rep; 2016 Nov; 6():37051. PubMed ID: 27845387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-capacity adenovector delivery of forced CRISPR-Cas9 heterodimers fosters precise chromosomal deletions in human cells.
    Tasca F; Brescia M; Liu J; Janssen JM; Mamchaoui K; Gonçalves MAFV
    Mol Ther Nucleic Acids; 2023 Mar; 31():746-762. PubMed ID: 36937620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives.
    Chen G; Wei T; Yang H; Li G; Li H
    Cells; 2022 Sep; 11(19):. PubMed ID: 36230926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing.
    Min YL; Chemello F; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Mireault AA; McAnally JR; Shelton JM; Zhang Y; Bassel-Duby R; Olson EN
    Mol Ther; 2020 Sep; 28(9):2044-2055. PubMed ID: 32892813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transiently expressed CRISPR/Cas9 induces wild-type dystrophin in vitro in DMD patient myoblasts carrying duplications.
    Pini V; Mariot V; Dumonceaux J; Counsell J; O'Neill HC; Farmer S; Conti F; Muntoni F
    Sci Rep; 2022 Mar; 12(1):3756. PubMed ID: 35260651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of Duchenne muscular dystrophy cellular model using CRISPR-Cas9 exon deletion strategy.
    Alizadeh F; Abraghan YJ; Farrokhi S; Yousefi Y; Mirahmadi Y; Eslahi A; Mojarrad M
    Mol Cell Biochem; 2024 May; 479(5):1027-1040. PubMed ID: 37289342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice.
    Zhang Y; Long C; Li H; McAnally JR; Baskin KK; Shelton JM; Bassel-Duby R; Olson EN
    Sci Adv; 2017 Apr; 3(4):e1602814. PubMed ID: 28439558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
    Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
    Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.